The trajectory of Sildenafil website presents a nuanced case for stakeholders in the drug sector. While initially a phenomenal success, producing huge profits, the patent lapse and the subsequent flood of generic alternatives have significantly changed income. This raises questions about the future profitability of related therapeutic developments